PASSAGE BIO, INC. (PASG) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$8.25M*; Operating income -$8.27M; Depreciation and amortization $25.00K*.
- 2026-03-31: Basis Reported; EBITDA -$8.12M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$13.67M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$8.46M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2019-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$8.25M* | -$8.27M | $25.00K* | (m) | (m) | (m) | -$9.18M* | (m) | $3.34M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$8.12M | (m) | (m) | (m) | (m) | (m) | -$12.99M | (m) | $4.09M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$13.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$8.46M | (m) | (m) | (m) | (m) | (m) | -$4.85M* | (m) | $4.31M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$10.13M | (m) | (m) | (m) | (m) | (m) | -$6.33M* | (m) | $5.81M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$16.26M | (m) | (m) | (m) | (m) | (m) | -$13.85M | (m) | $7.74M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$13.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$19.9M | (m) | (m) | (m) | (m) | (m) | -$7.45M* | (m) | $8.66M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$16.58M | (m) | (m) | (m) | (m) | (m) | -$13.14M* | (m) | $10.43M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$17.24M | (m) | (m) | (m) | (m) | (m) | -$18.93M | (m) | $11.54M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$17.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$27.67M | (m) | (m) | (m) | (m) | (m) | -$19.16M* | (m) | (m) | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$24.39M | (m) | (m) | (m) | (m) | (m) | -$17.14M* | (m) | (m) | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$34.91M | (m) | (m) | (m) | (m) | (m) | -$22.45M | (m) | (m) | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$27.3M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$26.63M | (m) | (m) | (m) | (m) | (m) | -$23.39M* | (m) | (m) | (m) | (m) |
|---|
| 2022-06-30 | Reported | -$38.91M | (m) | (m) | (m) | (m) | (m) | -$26.08M* | (m) | (m) | (m) | (m) |
|---|
| 2022-03-31 | Reported | -$41.93M | (m) | (m) | (m) | (m) | (m) | -$44.71M | (m) | (m) | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$50.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$46.64M* | -$47.10M | $460.00K* | (m) | (m) | (m) | -$41.06M* | (m) | (m) | (m) | (m) |
|---|
| 2021-06-30 | Reported | -$48.33M* | -$48.53M | $203.00K* | (m) | (m) | (m) | -$24.33M* | (m) | (m) | (m) | (m) |
|---|
| 2021-03-31 | Reported | -$38.72M | (m) | (m) | (m) | (m) | (m) | -$30.72M | (m) | (m) | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$38.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$28.36M* | -$28.63M | $275.00K* | (m) | (m) | (m) | -$17.53M* | (m) | (m) | (m) | (m) |
|---|
| 2020-06-30 | Reported | -$27.11M* | -$27.30M | $198.00K* | (m) | (m) | (m) | -$11.71M* | (m) | (m) | (m) | (m) |
|---|
| 2020-03-31 | Reported | -$17.86M | (m) | (m) | (m) | (m) | (m) | -$21.85M | (m) | $13.12M | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$13.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2019-09-30 | Reported | -$11.60M* | -$11.64M | $41.00K* | (m) | (m) | (m) | -$11.42M* | (m) | (m) | (m) | (m) |
|---|
| 2019-06-30 | Reported | -$7.73M* | -$7.77M | $36.00K* | (m) | (m) | (m) | -$10.78M* | (m) | (m) | (m) | (m) |
|---|
| 2019-03-31 | Reported | (m) | (m) | $12.00K | (m) | (m) | (m) | -$214.00K | (m) | (m) | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$48.57M | (m) | (m) | (m) | (m) | (m) | -$31.51M | (m) | $23.28M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$67.32M | (m) | (m) | (m) | (m) | (m) | -$47.96M | (m) | $40.18M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$104.67M | (m) | (m) | (m) | (m) | (m) | -$78.26M | (m) | $61.42M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$134.72M | (m) | (m) | (m) | (m) | (m) | -$118.21M | (m) | (m) | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$184.19M | (m) | (m) | (m) | (m) | (m) | -$126.88M | (m) | (m) | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$112.1M | (m) | (m) | (m) | (m) | (m) | -$80.52M | (m) | (m) | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$37.06M | (m) | (m) | (m) | (m) | (m) | -$39.90M | (m) | $3.03M | (m) | (m) |
|---|